Characterization of MHC Class I and β‐2‐Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune‐Based Therapeutic Trials
Kellie B. Haworth(Nationwide Children's Hospital), Timothy P. Cripe(Nationwide Children's Hospital), Brian Hutzen(Nationwide Children's Hospital), Ryan D. Roberts(Nationwide Children's Hospital), Hayley M. Swain(Nationwide Children's Hospital), Jennifer L. Leddon(University of Cincinnati), Michael Arnold(Children's Hospital Colorado), Christopher R. Pierson(Nationwide Children's Hospital), Dias Kurmashev(The University of Texas at San Antonio Health Science Center)
Cited by 16
Related Papers
MEF2C Transcription Factor Controls Chondrocyte Hypertrophy and Bone Development
|Developmental Cell|2007|457
Mre11 Nuclease Activity Has Essential Roles in DNA Repair and Genomic Stability Distinct from ATM Activation
|Cell|2008|341
Gray matter injury associated with periventricular leukomalacia in the premature infant
|Acta Neuropathologica|2007|315
Covalently Linked Au Nanoparticles to a Viral Vector: Potential for Combined Photothermal and Gene Cancer Therapy
|Nano Letters|2006|260
SPEG Interacts with Myotubularin, and Its Deficiency Causes Centronuclear Myopathy with Dilated Cardiomyopathy
|The American Journal of Human Genetics|2014|164